Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) - Noble Financial issued their FY2024 EPS estimates for shares of Zomedica in a research report issued on Monday, November 11th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.05) for the year. Noble Financial currently has a "Strong-Buy" rating on the stock. Noble Financial also issued estimates for Zomedica's Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.
Zomedica Trading Down 5.3 %
Shares of ZOM stock traded down $0.01 during mid-day trading on Thursday, hitting $0.14. The stock had a trading volume of 5,391,688 shares, compared to its average volume of 4,793,996. The stock has a market capitalization of $137.19 million, a price-to-earnings ratio of -2.47 and a beta of 1.06. Zomedica has a 12-month low of $0.12 and a 12-month high of $0.23.
Institutional Investors Weigh In On Zomedica
A hedge fund recently raised its stake in Zomedica stock. Price T Rowe Associates Inc. MD grew its holdings in Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 41.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 948,300 shares of the company's stock after acquiring an additional 276,100 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.10% of Zomedica worth $139,000 at the end of the most recent reporting period. 8.95% of the stock is owned by institutional investors.
About Zomedica
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Featured Articles
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
